Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO.

Plus, news about Lexicon Pharmaceuticals, Vaxcyte, ALX Oncology, BioMarin and 2048 Ventures:

EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease.

The White House is punting the launch of TrumpRx, the administration’s hub for direct-to-consumer websites run by large drugmakers.

Yosemite, the cancer research investment firm led by Reed Jobs, is looking to raise a fund worth up to $350 million, according to a Thursday SEC filing.

✂️ Sanofi culls several programs: The move comes as part of its “regular portfolio reviews,” a spokesperson said in an email. One candidate affected was amlitelimab, which is no longer in mid-stage trials for alopecia ...